New hope for dialysis patients who can't use standard blood thinners

NCT ID NCT06150742

Recruiting now Disease control Sponsor: Talphera, Inc Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tests a drug called Niyad as a blood thinner for people with acute kidney injury who need continuous dialysis but cannot use the standard drug heparin or are at high risk for bleeding. About 70 participants will receive either Niyad or a placebo to see if it safely prevents blood clots in the dialysis filter. The goal is to keep the dialysis machine working effectively without causing dangerous bleeding.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ACUTE KIDNEY INJURY are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

acute kidney injury

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

ACUTE KIDNEY INJURY

Contacts and locations

Locations

AdventHealth
NOT_YET_RECRUITING

Orlando, Florida, 32804, United States
Baylor University Medical Center
RECRUITING

Dallas, Texas, 75246, United States
Cincinnati Children's Hospital Medical Center
RECRUITING

Cincinnati, Ohio, 45229, United States
Henry Ford Health
RECRUITING

Detroit, Michigan, 48202, United States
Medical University of South Carolina
RECRUITING

Charleston, South Carolina, 29425, United States
Mount Sinai
RECRUITING

New York, New York, 10029, United States
Northwell Health
RECRUITING

Great Neck, New York, 11021, United States
University of California Los Angeles
RECRUITING

Los Angeles, California, 90095, United States
University of New Mexico
RECRUITING

Albuquerque, New Mexico, 87131, United States
University of Pittsburgh Medical Center
RECRUITING

Pittsburgh, Pennsylvania, 15213, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.